The present invention demonstrates that chronic active BCR signaling through CD79A/B confers a strong dependence on downstream PKCb kinase signaling. Hence provided herein is a method for inhibiting the growth of B cell lymphoma having chronic active B cell receptor signaling or inhibiting the growth of cancers with molecular lesions that lead to chronic active BCR signaling by administering to a patient in need of such treatment a therapeutically effective amount of a PKC inhibitor or a use of a PKC inhibitor to inhibit the growth of B cell lymphoma having chronic active B cell receptor signaling or to inhibit the growth of cancers with molecular lesions that lead to chronic active BCR signaling.
